Aeglea BioTherapeutics
normalization of plasma arginine levels in patients | Aeglea BioTherapeutics
Company
Deck Type
Sector
Industry
Deck date
February 2022
Slide
26 of 33
Similar slides by Aeglea BioTherapeutics
See diffirences between slides (animation)
Results
December 2021
normalization of plasma arginine levels in patients | Aeglea BioTherapeutics
Related slides by other companies
Kymera
Results
December 2022
interim safety data summary patients at dose level all patients heavily prior lines solid tumor no no treatment related no aes leading to discontinuation | Kymera
argenx SE
Investor Day
July 2021
patients respond to | argenx SE
ATAI
Investor Presentation
October 2022
comparable dose typically results in a cadss score of placebo cadss score of or below is considered normal minutes minutes minutes phase data doses that were selected for phase a | ATAI
Renovacor
SPAC
October 2022
mutations in bag reduce levels of protein and are associated with reduced force generating capacity in heart tissue from patients | Renovacor
Other recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io